Low-dose All-trans Retinoic Acid for Remission Induction of Acute Promyelocytic Leukemia in Acute Renal Failure.
10.5045/kjh.2006.41.2.105
- Author:
Hye Won PARK
1
;
Ju Hyun CHOI
;
Danbi LEE
;
Dong Hoe KOO
;
Ja Eun KOO
;
Sai Hui KIM
;
Je Hwan LEE
;
Jung Hee LEE
;
Kyoo Hyung LEE
Author Information
1. Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. khlee2@amc.seoul.kr
- Publication Type:Case Report
- Keywords:
All-trans retinoic acid;
Renal insufficiency;
Acute promyelocytic leukemia
- MeSH:
Acute Kidney Injury*;
Adult;
Azotemia;
Ecchymosis;
Female;
Hematologic Neoplasms;
Humans;
Idarubicin;
Intensive Care Units;
Leukemia, Promyelocytic, Acute*;
Oliguria;
Remission Induction*;
Renal Insufficiency;
Renal Replacement Therapy;
Tretinoin*
- From:Korean Journal of Hematology
2006;41(2):105-109
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
All-trans retinoic acid (ATRA) is the standard induction treatment for acute promyelocytic leukemia (APL). Renal involvement sometimes necessitates a dose reduction or discontinuation of induction therapy for hematological malignancies. We report here on a case of APL that achieved complete remission with low-dose ATRA treatment despite the patient's acute renal failure. A 42-year-old woman presented with a 2 month history of ecchymosis and she was subsequently diagnosed with APL. During induction treatment with ATRA and idarubicin, oliguria developed and her azotemia rapidly progressed. Because of the progressive deterioration in her general condition, the patient was transferred to the intensive care unit. We started renal replacement therapy for her acute renal failure and we discontinued ATRA treatment. Her urine output started to increase, and there was an improvement in the patient's general condition. We resumed low-dose ATRA treatment. She achieved complete remission after 52 days of treatment.
